Shaun Chilton to take over as Chief Executive Officer
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services group, has been notified by Peter George that he intends to step down as Chief Executive Officer (‘CEO’) on 11 November 2016. He will continue as a non executive director.
Shaun Chilton, who has been Deputy CEO since July 2015 and before that Chief Operating Officer for over three years, will become CEO on that date.
Separately Robin Sibson, who has served as non executive director since 2015 and before that as the Group’s Chief Financial Officer, has notified the Board that he intends to retire from the Board at the AGM in November.
Peter Allen, Chairman said:
“Peter has done a tremendous job developing and growing Clinigen over the last six years.
“He built the business from a small private company to its current position as a leading global pharmaceutical products and services business with a market capitalisation of some £800m. He led the IPO four years ago and the two substantial transformational acquisitions over the last 18 months.
“The Board looks forward to working with Shaun. He has held a number of senior roles in Clinigen over the last four years and been closely involved in its development. He has the international industry knowledge, expertise and leadership skills to take this business forward.
“I would also like to thank Robin for his continued contribution to the business since he became a non executive director just over a year ago.”
Peter George, CEO, Clinigen said:
“It has been a pleasure and privilege to create and lead Clinigen over the last six years with the IPO, strong organic growth and the two recent transformational acquisitions being the highlights. I would like to thank all of the Group’s employees around the world - we have been only able to create this substantial business thanks to their hard work and commitment.
“I have worked closely with Shaun over the years and I would like to thank him for his invaluable contribution. I look forward to supporting him as he takes the business to the next stage in its development.”
Shaun Chilton, CEO-designate said:
“I am delighted to have the opportunity to lead Clinigen. We have been building the Group’s infrastructure, capabilities, IP and geographical footprint over the last four years, creating a unique business model with a top quality management team.
“Our focus now is to drive sustainable growth by capitalising on our market leading positions in clinical trial services and unlicensed medicines and continuing to expand our portfolio of specialty pharmaceuticals.”
Clinigen Group plc
Tel: +44 (0) 1283 495 010
Peter Allen, Chairman
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard (Corporate Broking)
Peel Hunt LLP - Joint Broker
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Tel: +44 (0) 20 7457 2020
Adrian Duffield / Melanie Toyne-Sewell
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.